C-RQTQMogling Bio
Cdc42 inhibition, CASIN, stem cell rejuvenation
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-RQTQ
C-RQTQC-RQTQCdc42 inhibition, CASIN, stem cell rejuvenation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
In diesem Podcast spreche ich mit Prof. Dr. Hartmut Geiger. Der Leiter des Instituts für molekulare Medizin an der Universität in Ulm und wissenschaftliche Kopf des StartUps Mogling Bio ist der Meinung „Alterung ist einfach Unordnung in der Zelle. Das Wiederherstellen der Ordnung führt zur Verjüngung.“ In dieser Folge erfährst du: - Wie das Zitat zu verstehen ist. - Wie diese Unordnung in den Zellen entsteht. - Wie Prof. Dr. Hartmut Geiger die Ordnung wieder herstellen will. - Wie weit sein StartUp mit ihrer Entwicklung sind. - Wo der Unterschied zwischen angeborenen und adaptiven Immunsystem ist - Und wie sich die beiden im Alter entwickeln. - Warum wir bei den Stammzellen auch von dem „Gedächtnis der Zelle“ sprechen. Weitere Informationen zu Prof. Dr. Hartmut Geiger und Mogling Bio findest du hier: https://www.geigerlab.com/ https://www.moglingbio.com/ Du interessierst dich für Gesunde Langlebigkeit (Longevity) und möchtest ein Leben lang gesund und fit bleiben, dann folge m
Aging is a dynamic process characterized by the accumulation of cell damage, tissue, and organ degeneration, and diminished function. This process of decline appears to be an inevitable aspect of human existence. In recent years, however, advancements in scientific understanding of aging bring us closer to extending the human lifespan. With their guests, Prof. Jürgen Reess and Prof. Hartmut Geiger, founders of Moglingbio, Louise von Stechow and Andreas Horchler explore the complex science underlying the process of aging and the challenges faced by the budding longevity industry. They talk about the potential for rejuvenating aged cells in human tissues and the ethical considerations of extending the human lifespan. #ageing #biotechnology #cellrepair #scientificrevolution #pharma Content and Editing: Louise von Stechow and Andreas Horchler Disclaimer: Louise von Stechow & Andreas Horchler and their guests express their personal opinions, which are founded on research on the respecti
Mogling Bio Inc — NIH Funding & Grants | ConductScience Science Dex Institutions Investigators Medical Schools Methods Datasets Browse Grant Tools Shop Equipment Home / Institutions / Mogling Bio Inc MBI Mogling Bio Inc Cincinnati , OH · Other NIH Rank # 2331 NIH Funding · FY 2024 Total Funding $299.8K Fiscal year 2024 Grants Awarded 1 Active NIH grants Funded PIs 2 Principal investigators National Rank #2,331 Among 2,359 institutions Funding & rank history NIH funding totals and national rank by fiscal year. Top departments by funding Department-level NIH funding breakdown for Mogling … nded principal investigators Highest-funded PIs at Mogling Bio Inc based on NIH grant totals. # 1 Yi Zheng 1 grant $299.8K total funding # 2 James C Mulloy 1 grant $299.8K total funding Explore further Find collaborators at Mogling Bio Inc Search NIH-funded principal investigators by topic, department, or activity. Open Find Collaborators → Check S10 eligibility for Mogling Bio Inc Review past S10 Shared Instrumentation Grant awards and equipment categories. Open S10 Eligibil … igators Explore Geographic Rankings Disciplines Overview Datasets About Methods Grant Planning Tools ConductScience ConductScience.com Lab Equipment Free Tools Data from NIH RePORTER . © 2026 ConductScience
Mogling Bio Skip to main content Home Science Team News/Press Partnering Contact Zurück Timothy S. Tracy, PhD Tim is a clinical pharmacologist with over 30 years of experience in pharmaceutical research and drug development. A Fellow of the American Association of Pharmaceutical Scientists, he holds three patents related to drug delivery systems and has published over 100 scientific manuscripts, twenty book chapters and edited three books. Tim’s expertise is in the areas of drug metabolism, pharmacokinetics and pharmacogenetics, as well as the larger field of clinical pharmacology and he has c
CDC42 - Drugs, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 30 Sep 2024 CDC42 Last update 30 Sep 2024 Basic Info Related Targets CDC42 Related 11 Drugs associated with CDC42 MBQ-167 Target CDC42 Mechanism CDC42 inhibitors Active Org. University of Puerto Rico-RÃo Piedras [+1] Originator Org. University of Puerto Rico-RÃo Piedras Active Indication Advanced breast cancer [+1] Inactive Indication - Drug Highest Phase Phase 1 First Approval Ctry. / Loc. - First Approval Date - NCGC00098561 Target CDC42 Mechanism CDC42 inhibitors Active Org. … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Cyclarity Therapeutics, Revel Pharmaceuticals, Elastrin Therapeutics, LIfT BioSciences and others. For more information, please visit: About Mogling Bio Mogling Bio Inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Aging causes stem cells to lose their normal structure by incr
Stammzellenverjüngung ist mögl ... – staYoung - Der Longevity-Podcast – Apple Podcasts Suchen Startseite Neu Top-Charts Suchen 5. Juli 2024 46 Min. Stammzellenverjüngung ist möglich – Prof. Dr. Hartmut Geiger will die Alterung umkehren staYoung - Der Longevity-Podcast Wiedergeben In diesem Podcast spreche ich mit Prof. Dr. Hartmut Geiger. Der Leiter des Instituts für molekulare Medizin an der Universität in Ulm und wissenschaftliche Kopf des StartUps Mogling Bio ist der Meinung „Alterung ist einfach Unordnung in der Zelle. Das Wiederherstellen der Ordnung führt zur Verjüngung.“ In dieser Folge
Erste deutsche Startups arbeiten an Langlebigkeit und Verjüngung - Business Insider Direct naar de inhoud Abo Einloggen Registrieren Mein Konto Abonnent werden Best of GS+ Best of GS+ FAQ Prämienprogramm Newsletter Newsletter Insider (US) Abmelden Magazin Business Technologie Fintech Food Health Karriere Perspektive Mobility Plus Whistleblowing Events Newsletter Podcast Royal GS Cashburners Über uns Autoren Mediadaten Brand Storys BI weltweit Deutschland & Österreich US Zwei Newsrooms in einer App Wirtschaftsnachrichten & Startup-News direkt auf dein Smartphone Copyright © 2026 Axel Sp … iebe biotechnologische Startups finanzieren. Darunter sind der Longevity Vision Fund (lvf.vc) und der Longevity Fund (longevity.vc) die berühmtesten. Auch in Deutschland seien bereits mit Apollo Health Ventures und Korify Capital erste Spezialisten-Fonds aktiv geworden, berichtet das Handelsblatt. In Deutschland steckt Longevity noch in den Kinderschuhen Oder der Berliner Wagniskapitalgeber Kizoo, der nun Millionen in das Startup Mogling Bio investiert hat. Mogling Bio, vom S
Mogling Bio Skip to main content Home Science Team News/Press Partnering Contact Publication A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells Read full paper here Contact Mogling Bio 2900 Reading Road Suite #410 Cincinnati OH 45206 Dr. Juergen Reess [email protected] Privacy policy Copyright Policy Terms of Use
Handelsblatt Please enable JavaScript to continue using this application.
RTL+: Sieh dir TV-Programme live und in der Wiederholung an Start Alles Serien Filme Shows Themenwelten Live-TV Sport Audio Suche Paket wählen Stammzellenverjüngung ist möglich – Prof. Dr. Hartmut Geiger will die Alterung umkehren Stammzellenverjüngung ist möglich – Prof. Dr. Hartmut Geiger will die Alterung umkehren staYoung - Der Longevity-Podcast Abspielen Mehr Details Mehr Details 05.07.2024 • 46 Min. In diesem Podcast spreche ich mit Prof. Dr. Hartmut Geiger. Der Leiter des Instituts für molekulare Medizin an der Universität in Ulm und wissenschaftliche Kopf des StartUps Mogling Bio ist d
Stammzellenverjüngung ist mögl… ‑ staYoung - Der Longevity-Podcast ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 5 juillet 2024 46 min Stammzellenverjüngung ist möglich – Prof. Dr. Hartmut Geiger will die Alterung umkehren staYoung - Der Longevity-Podcast Lire In diesem Podcast spreche ich mit Prof. Dr. Hartmut Geiger. Der Leiter des Instituts für molekulare Medizin an der Universität in Ulm und wissenschaftliche Kopf des StartUps Mogling Bio ist der Meinung „Alterung ist einfach Unordnung in der Zelle. Das Wiederherstellen der Ordnung führt zur Verjüngung.“ In dieser F
Longevity Investors Conference 2024 | Startup Innovation Showcase - Mogling Bio - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Mogling Bio Skip to main content Home Science Team News/Press Partnering Contact Rejuvenation Startup Summit 2024 Juergen Reess, Co-founder and CEO of MoglingBio presenting at the Rejuvenation Startup Summit 2024 Contact Mogling Bio 2900 Reading Road Suite #410 Cincinnati OH 45206 Dr. Juergen Reess [email protected] Privacy policy Copyright Policy Terms of Use
Mogling Bio-VCBeat VCBeat Health Contact Us Home China Healthcare Select Insights MNC China Lens Vertical Industries Services Partnership Development Market Entry Advisory Ecosystem Engagement Advisory About VCBeat Why VCBeat Log In Home Mogling Bio Mogling Bio In operation Seed Round Financing Biotechnology Researcher Basic Information Mogling Bio is developing new pharmacological approaches to rejuvenate aged stem cells. As we age, the internal structure of blood cell-forming stem cells, also known as hematopoietic stem cells (HSCs), becomes disordered. This leads to impaired productio
Mogling Bio Skip to main content Home Science Team News/Press Partnering Contact Website Terms of Use Last modified: December, 2022 Acceptance of the Terms of Use These terms of use are entered into by and between You and Mogling Bio Inc. (“ Company ,” “ we ,” or “ us ”). The following terms and conditions, together with any documents they expressly incorporate by reference (collectively, “ Terms of Use ”) govern your access to and use of www.moglingbio.com , including any content, functionality, and services offered on or through www.moglingbio.com (the “ Website ”). Please read the … r sole discretion. All changes are effective immediately when we post them, and apply to all access to and use of the Website thereafter. However, any changes to the dispute resolution provisions set out in Governing Law and Jurisdiction will not apply to any disputes for which the parties have actual notice before the date the change is posted on the Website. Your continued use of the Website following the posting of revised Terms of Use means that you accept and agree to th
Mogling Bio Skip to main content Home Science Team News/Press Partnering Contact Mogling Bio signs exclusive CASIN Licensing agreement Mogling Bio entering Licensing Agreement with Cincinnati Children’s Hospital Medical Center Mogling Bio Inc., a privately owned, preclinical stage biopharmaceutical company, announced it has entered into a global and exclusive licensing agreement with Cincinnati Children’s Hospital Medical Center for CASIN, a CDC 42 inhibitor being developed for rejuvenation of hematopoietic stem cells. Mogling Bio stated this might become a treatment option for certain forms o
Mogling Bio Profile | fundable. fundable. DATA PLATFORM Dashboard Companies People Investment Firms Angels & Partners COLLECTIONS Lists Saved Searches Hiring Lists WORKFLOWS Deal Alerts Integrations API Toggle Sidebar Overview Highlights Financials Team Mogling Bio Recent Finacing Seed Recent Raise Undisclosed Mogling Bio is a German biotech company developing pharmacological therapies to rejuvenate aged hematopoietic stem cells and restore immune system function. Founded 2022 Delaware, United States 1-10 Private moglingbio.com Highlights Focus Areas Health Care Medical Recent Investors Fi
Mogling Bio Inc — NIH Funding & Grants | ConductScience Science Dex Institutions Investigators Medical Schools Methods Datasets Browse Grant Tools Shop Equipment Home / Institutions / Mogling Bio Inc MBI Mogling Bio Inc Cincinnati , OH · Other NIH Rank # 2331 NIH Funding · FY 2024 Total Funding $299.8K Fiscal year 2024 Grants Awarded 1 Active NIH grants Funded PIs 2 Principal investigators National Rank #2,331 Among 2,359 institutions Funding & rank history NIH funding totals and national rank by fiscal year. Top departments by funding Department-level NIH funding breakdown for Mogling … nded principal investigators Highest-funded PIs at Mogling Bio Inc based on NIH grant totals. # 1 Yi Zheng 1 grant $299.8K total funding # 2 James C Mulloy 1 grant $299.8K total funding Explore further Find collaborators at Mogling Bio Inc Search NIH-funded principal investigators by topic, department, or activity. Open Find Collaborators → Check S10 eligibility for Mogling Bio Inc Review past S10 Shared Instrumentation Grant awards and equipment categories. Open S10 Eligibil … igators Explore Geographic Rankings Disciplines Overview Datasets About Methods Grant Planning Tools ConductScience ConductScience.com Lab Equipment Free Tools Data from NIH RePORTER . © 2026 ConductScience
Stem Cell Rejuvenation Technology Licensed to Mogling Bio - Research Horizons Research Horizons Home Findings Features Announcements Learning Newsletter Subscribe Subspecialty News All Categories Announcements Features Findings Learning & Networking Search Search Home Findings Features Announcements Learning Newsletter Subscribe Subspecialty News Home Announcements Cancer Stem Cell Rejuvenation Technology Licensed to Mogling Bio Stem Cell Rejuvenation Technology Licensed to Mogling Bio Research By: Yi Zheng, PhD Post Date: September 13, 2023 | Publish Date: Share on X Share on LinkedIn Sha … an in 2006, when Zheng discovered that gene targeting CDC42 in mouse models and application of CASIN, a naturally occurring CDC42 inhibitor, could effectively open the bone marrow niche, enabling stem cells to enter the blood stream. This breakthrough held potential implications for gene therapies targeting genetic blood disorders like sickle cell disease and paved the way for research on therapeutics that rejuvenate aged HSCs. As research progressed, Zheng and his colleagues
Mogling Bio Skip to main content Home Science Team News/Press Partnering Contact Zurück Dr. Yi Zheng, PhD, co-founder, Scientific Advisor Yi is a biochemist and has over 30 years of experience studying the mechanistic role of Rho family GTPases including Cdc42. He is a Professor and Co-Director, Cancer and Blood Diseases Institute, and Leader of the Signaling and Drug Discovery Program at Cincinnati Children’s Research Foundation. His academic career has been continuously supported by US National Institutes of Health, Department of Defense, American Cancer Society, as well as private foundatio
Jürgen Reess - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Jürgen Reess Board Member at Cyxone AB Jürgen Reess 's Executive Work History Current Board Member , Board Member Equilar on 10/22/2024 Cyxone AB Past To view Jürgen Reess's complete executive work history, sign up now Education European Institute of Busin
Kizoo invests in rejuvenation startup MoglingBio Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search HAYA Therapeutics begins do... CellProthera … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Cyclarity Therapeutics, Revel Pharmaceuticals, Elastrin Therapeutics, LIfT BioSciences and others. MoglingBio is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Aging causes stem cells to lose their normal structure by increased activity of the protein CDC42. This loss of structure
Jürgen Reess MoglingBio Inc. [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News T-Curx GmbH Acquires Pantherna Therapeutics GmbH Lilly: 3 Acquisitions to Build Infectious Disease Portfolio Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Qiagen Announces Collaboration with Nvidia at Bio-IT World Bilfinger: £15m Biopharma Maintenance Contract in Scotland Lauxera Capital Partners Closes Growth II Fund at €520m Hansa Biopha … rlet Therapeutics Closes £3.2m Seed Round Led by Eos » More News! » Submit your News! Upcoming Events Future Labs Live 2026 Basel LSN Health & Life Science Venture Day 2026 Hamburg William Blair & Company Annual Growth Stock Conference 2026 Chicago Jefferies 2026 Global Healthcare Conference New York SaxoCell Conference 2026 Dresden Festival of Genomics & Biodata 2026 Boston IHMC 2026 Seoul (International Human Microbiome Consortium Congress 2026) Knowledge for Gr … it 2026 Leipzig EUROMAR 2026 Gothenburg (Göteborg) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camila Japur Joins Tecan as CFO on 1 Jun 2026 Birgit Girshick Succ … c Appoints Ashiq H. Khan as Chief Commercial Officer » More News! » Submit your News! Financings & Acquisitions InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange Roche to Acquire PathAI for up to $1.05b Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1b Scarlet Therapeutics Closes £3.2m Seed Round Led by Eos CellCentric Announces $220m Serie … Has Acquired the IMIDomics’ Patient Insight Business » More News! » Submit your News! Collaborations & Licensing Hansa Biopharma: €115m Licensing Agreement with SERB GSK Licenses siRNA Oligo Drug from SiranBio for up to $1b Biesterfeld & Traceless Materials Form Strategic Partnership Medistrava Is Media Contact for Cytospire Therapeut
Elastrin Therapeutics - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 24 Feb 2026 Elastrin Therapeutics Startups | Holding Company | 2017 | South Carolina, United States | < 10 | www.elastrin.com Startups | Holding Company | 2017 | South Carolina, United States | < 10 | www.elastrin.com Last update 24 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Cardiovascular Diseases Endocrinology and Metabolic Disease Biological products Monoclonal ant … and molecular level, with additional participation from previous investors R42 Fund and Healthspan Ventures. Reservoir’s unique approach to neurodegeneration was developed by co-founders Aaron Friedman and Vlad Senatorov, PhD neuroscientists from UC Berkeley who focus on understanding how aging blood vessels effect brain health. The company aims to develop the first drug that specifically targets vascular disease as a new way to restore brain health during natural aging and … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Cyclarity, Revel Pharmaceuticals, Elastrin Therapeutics, MoglingBio, and others. For more information, please visit: www.kizoo.com Media Contact for Kizoo Frank SchuelerManaging DirectorKizoo Technology [email protected] Media Contact for Reservoir Neuroscience Aaron FriedmanCEO Reservoir [email protected] 08 Nov 2023 · www.globenewswi … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Cyclarity Therapeutics, Revel Pharmaceuticals, Elastrin Therapeutics, LIfT BioSciences and others. For more information, please visit: About Mogling Bio Mogling Bio Inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Aging causes stem cells to lose their normal structure by incr … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Mogling Bio - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 17 Feb 2026 Mogling Bio Startups | Holding Company | 2022 | Delaware, United States | < 10 | www.moglingbio.com Startups | Holding Company | 2022 | Delaware, United States | < 10 | www.moglingbio.com Last update 17 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Mogling Bio Login to view more data 0 Patents (Medical) associated with Mogling Bi … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Cyclarity Therapeutics, Revel Pharmaceuticals, Elastrin Therapeutics, LIfT BioSciences and others. For more information, please visit: About Mogling Bio Mogling Bio Inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Aging causes stem cells to lose their normal structure by incr … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Mogling Bio Skip to main content Home Science Team News/Press Partnering Contact Zurück Dr. Jürgen Reeß, MD, co-founder, CEO Jürgen has over 20 years of experience in operative and strategic clinical development, most recently as the CEO and managing director of Cellerys AG. Prior to that, he was Corporate Senior Vice President of International Project Management at Boehringer Ingelheim Human Pharma. A trained physician with a medical and doctorate degree from the University of Ulm (Germany), he is a board-certified neurologist and a leader in the pharmaceutical industry. He supervised t
Mogling Bio - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks C … ed Year 2022 Location Wilmington, United States Stage Seed Latest Funding Round Grant (prize money), Sep 23, 2024 , $***** Investors Kizoo & 1 more Ranked 66 th among 95 active competitors Similar Companies MaaT Pharma & 98 more View Mogling Bio's full profile Sign up to download Mogling Bio's company profile Sign Up for Free Mogling Bio's funding and investors Mogling Bio has raised funding over 3 round s . Its first funding round was on Oct 26, 2022 . … . Its first funding round was on Oct 26, 2022 . Its latest funding round was a Grant (prize money) round on Sep 23, 2024 for $ ***** . 1 investor participated in its latest round. Mogling Bio has 2 institutional investor s . Here is the list of recent funding rounds of Mogling Bio : Date of Funding Funding Amount Round Name Post-Money Valuation Revenue Multiple Lead Investors Other Investors Sep 23, 2024 5791659 Grant (prize money) 7022434 8182013 8501348 2254133 Nov 06, 202 … t funding round of Mogling Bio? Mogling Bio's latest funding was a $ ***** Grant (prize money) round on Sep 23, 2024 , with participation from 1 investor . Who are the top competitors of Mogling Bio? Mogling Bio's top competitors include MaaT Pharma , Ossium Health and Adicet Bio . Among them, Orca Bio secured the most recent funding round in January, 2026 . What does Mogling Bio do? Developer of cell-based therapeutics for blood cancer. It offers drugs to inhibit t
Rejuvenation | M. Carolina Florian LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Cyclarity, Revel Pharmaceuticals, Elastrin Therapeutics, Mogling Bio, and others. For more information, please visit: kizoo.com For media inquiries, please contact: Juergen Reess MoglingBio [email protected] +49 178 290 5580 Rejuvenation moglingbio.com 13 1 Comment Like Comment Share Copy LinkedIn Facebook X Annette Albers 2y Report this comment
Kizoo invests in Rejuvenation Startup Mogling Bio - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All Ne … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Kizoo invests in Rejuvenation Startup Mogling Bio October 26, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Mogling Bio, a privately held biotech company, announces that it has successfully completed its first seed investment round. Mogling Bio closes Seed Investment Round with Kizoo Technology Capital BERLIN … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Cyclarity Therapeutics, Revel Pharmaceuticals, Elastrin Therapeutics, LIfT BioSciences and others. For more information, please visit: www.kizoo.com About Mogling Bio Mogling Bio Inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Aging causes stem cells to lose their normal str … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Mogling Bio Skip to main content Home Science Team News/Press Partnering Contact Kizoo invests in Seed Financing for Rejuvenation Startup MoglingBio Mogling Bio closes Seed Investment Round with Kizoo Technology Capital Berlin/Ulm, Germany - October 26, 2022 – Mogling Bio, a privately held biotech company, announces today that it has successfully completed its first seed investment round. Sole investor is venture capital firm Kizoo Technology Capital, a rejuvenation biotech investor focused on startups reversing age-related damage on a cellular and molecular level. Mogling Bio i … ning research on the root causes of aging into therapies and services for human application. Investments include Cellvie, Cyclarity Therapeutics, Revel Pharmaceuticals, Elastrin Therapeutics, LIfT BioSciences and others. For more information, please visit: www.kizoo.com About Mogling Bio Mogling Bio Inc. is developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. Aging causes stem cells to lose their normal str
Mogling Bio Skip to main content Home Science Team News/Press Partnering Contact Rejuvenation of (stem) cells Redefining the extension of Healthspan at the Cellular Level At Mogling Bio , we are pioneering pharmacological solutions to restore the function of aged and exhausted cells—particularly stem cells—addressing a root cause of tissue degeneration and age-related diseases. Our platform targets cellular aging to unlock new pathways for regenerative health, with the ultimate goal of compressing morbidity and extending Healthspan. We are advancing a new class of therapeutics positioned at th
Mogling Bio Skip to main content Home Science Team News/Press Partnering Contact Rejuvenation of Old Stem Cells Hartmut Geiger talks about his research on aging and stem cells and the influence of Casin on the biology. Contact Mogling Bio 2900 Reading Road Suite #410 Cincinnati OH 45206 Dr. Juergen Reess [email protected] Privacy policy Copyright Policy Terms of Use
Mogling Bio Skip to main content Home Science Team News/Press Partnering Contact Zurück Dr. Hartmut Geiger, PhD, co-founder, Scientific Advisor Hartmut has over 25 years of experience in academic research specializing on stem cell biology. Currently he is Professor and Director of the Institute of Molecular Medicine, Ulm University. Prior to that, he was a Professor at Cincinnati Children’s Research Foundation. His scientific interests lie in the molecular and cellular mechanisms of hematopoiesis, hematopoietic stem cell regulation and related immunologic functions. Together with the co-